Stability of Propranolol Hydrochloride in SyrSpend SF

Geiger, Christine M; Voudrie, Mark A II; Sorenson, Bridget

Abstract

Stability of Propranolol Hydrochloride in SyrSpend SF

Author(s): Geiger Christine M, Voudrie Mark A II, Sorenson Bridget

Issue: Nov/Dec 2012 - Volume 16, Number 6

View All Articles in Issue

Page(s): 513-515

Download in electronic PDF format for $75

Note: Electronic version includes errata or revisions.

Abstract

Propranolol hydrochloride is a beta blocker used to treat high blood pressure, abnormal heart rhythms, heart disease, pheochromocytoma, and certain types of tremors. Propranolol is marketed by Wyeth (now a part of Pfizer) and AstraZeneca under the brand names Inderal, Inderal LA, Avlocardyl, Deralin, Dociton, Inderalici, InnoPran XL, Sumial, Anaprilium, Bedranol SR (Sandoz). It is also available generically from several manufacturers. Propranolol hydrochloride is available as tablet, capsule, and oral liquid dosage forms in several strengths. Some patients are unable to tolerate oral tablets and capsules, challenging compounding pharmacies to seek alternative dosing options; namely oral solutions and suspensions. The objective of this study was to determine the stability of propranolol hydrochloride in SyrSpend SF. The drug was compounded into a 1-mg/mL suspension using SyrSpend SF and subsequently stored in a low actinic plastic prescription bottle at room temperature conditions. Six samples were assayed at each specific time point extending to 90 days by a stability-indicating high-performance liquid chromatography method. The method was validated for its specificity through forced-degradation studies. Based on the data collected, when protected from light at room temperature, the beyond-use date of propranolol hydrochloride in SyrSpend SF was shown to be at least 90 days.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Nov/Dec 2012 Pg. 513-515	Stability of Propranolol Hydrochloride in SyrSpend SF Author(s): Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
Jul/Aug 2018 Pg. 325	Propranolol Hydrochloride 1 mg/mL in SyrSpend SF Oral Suspension Author(s): Allen Loyd V Jr
Jul/Aug 2014 Pg. 330	Propranolol Hydrochloride 1-mg/mL Injection Author(s): Allen Loyd V Jr
Nov/Dec 2018 Pg. 516-526	Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4 Author(s): Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
Mar/Apr 2022 Pg. 148	Propranolol 2 mg/mL and 5 mg/mL in Ora-Blend SF Suspension Author(s): Allen Loyd V Jr
Nov/Dec 2015 Pg. 513	Propranolol Hydrochloride Capsules Author(s): Allen Loyd V Jr
Nov/Dec 2021 Pg. 504	Propranolol 2 mg/mL or 5 mg/mL in Ora-Sweet Author(s): Allen Loyd V Jr
Sep/Oct 2022 Pg. 364-368	A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans Author(s): Riepl Mike
Jul/Aug 2006 Pg. 304	Propranolol Hydrochloride 1-mg/mL Oral Liquid Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 194-197	Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality Author(s): Hagan John C III, Everett Eric, Chamberlain Tyler
Nov/Dec 2021 Pg. 503	Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2011 Pg. 358-366	Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Author(s): Zur Eyal
Nov/Dec 2007 Pg. 520-524	Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration Author(s): Ben Michel, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
Nov/Dec 2011 Pg. 458-463	Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers Author(s): Zur Eyal
May/Jun 2006 Pg. 220	Carvedilol 1.25-mg/mL Oral Suspension Author(s): Allen Loyd V Jr
Mar/Apr 1997 Pg. 125-127	Quantitation of Metoprolol Tartrate and Propranolol Hydrochloride in Pharmaceutical Dosage Forms: Stability of Metoprolol in an Aqueous Mixture Author(s): Gupta Vishnu D, Maswoswe J
Sep/Oct 2003 Pg. 389-393	Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride Author(s): Alexander Kenneth S, Thyangarajapuram N
May/Jun 2020 Pg. 252-262	Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4 Author(s): Polonini Hudson, Loures da Silva Sharlene, Neves Cunha Carolina, de Oliveira Ferreira Anderson, Anagnostou Korina, Dijkers Eli
Nov/Dec 2019 Pg. 494	Verapmail Hydrochloride 50 mg/mL in SyrSpend SF Author(s): Allen Loyd V Jr
Jan/Feb 2002 Pg. 66-69	Physical and Chemical Stability of Low and High Concentrations of Morphine Sulfate with Clonidine Hydrochloride Packaged in Plastic Syringes Author(s): Xu Quanyun A, Trissel Lawrence A, Pham Lien